Sort   by:  
 Page size 
TranscriptomicsRNAsequencing of WT Huh7 cells and lnc122-/miR-122+ Huh7 cells
to find out the lnc122(precursor of miR-122) role as an independent lncRNA, we designed the lnc122-/miR-122+ Huh7 cells with Lenti-CRISPRi_lnc122 + lenti-CAG-miR-122 combination. lenti-CRISPRi_lnc122 suppresses endogenous lnc122 as well as miR-122 but we add back the miR-122 ectopically.
ORGANISM(S): Homo sapiens 
2026-10-07 | E-MTAB-15726 | biostudies-arrayexpress
UnknownCharacterisation of the British honey bee metagenome.
Not available
S-EPMC6255801 | biostudies-literature
UnknownBacterial rhomboid proteases mediate quality control of orphan membrane proteins
Not available
S-SCDT-EMBOJ-2019-102922 | biostudies-other
Unknownp3k14c, a synthetic global database of archaeological radiocarbon dates.
Not available
S-EPMC8795199 | biostudies-literature
TranscriptomicsTranscriptional profiling of mouse bone marrow-derived macrophages (BMDMs) upon treatment with the S-palmitoylation inhibitor 2BP and/or myelin
The formation of inflammatory foamy macrophages hinders brain repair in multiple sclerosis. Therefore, the phenotype of the macrophages can determine the repair status of brain lesions. Here, we established the impact of the general S-palmitoylation inhibitor 2BP on the phenotype of bone marrow-deri...
ORGANISM(S): Mus musculus 
2026-10-27 | E-MTAB-15390 | biostudies-arrayexpress
UnknownLandscape of genomic alterations in cervical carcinomas.
Not available
S-EPMC4161954 | biostudies-literature
TranscriptomicsFate and State Transitions during Human Blood Vessel Organoid Development: Perturbation
Human blood vessel organoids (hBVOs) have emerged as a system to model human vascular development and disease. Here, we use genetic and signaling pathway perturbations to reconstruct hBVO development. We use single-cell genetic perturbations to identify transcription factors (TFs) and receptors invo...
ORGANISM(S): Homo sapiens 
2025-03-01 | E-MTAB-14839 | biostudies-arrayexpress
UnknownImmunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults.
Not available
S-EPMC11006114 | biostudies-literature
UnknownEvaluation of waning of IgG antibody responses after rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial.
Not available
S-EPMC11632942 | biostudies-literature
UnknownLong-term cellular immunity of vaccines for Zaire Ebola Virus Diseases.
Not available
S-EPMC11372064 | biostudies-literature
Sort   by:  
 Page size